Last reviewed · How we verify
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 in advanced colorectal cancer subjects.
Details
| Lead sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 130 |
| Start date | 2024-03-01 |
| Completion | 2026-06 |
Conditions
- Advanced Colorectal Cancer
Interventions
- SHR-A1811
- TAS-102, Regorafenib , Fruquintinib
Primary outcomes
- Progressive free survive assessed by Independent Review Committee — Every 6 weeks, up to 3 years
Countries
China